- Sees
opportunity in the passing of the new Farm Bill
- Signs
new chief sales officer to distribute CBD products nationwide
- Orders
first commercial production run of Hygee Kits
The passing of the new Farm Bill is big news for companies
like Earth Science Tech, Inc. (OTCQB: ETST) that work within the cannabis
industry. ETST is a Florida-based biotechnology company focused on cannabis and
cannabinoid research and development, nutraceuticals, pharmaceuticals and medical
devices. The newly passed 2018 Farm Bill removed hemp (including hemp-derived
cannabinoids containing less than 0.3 percent THC) from the Controlled
Substances act. According to New Frontier cannabis market data, the American
CBD market is now projected to reach $2.3 billion in revenue by 2022.
ETST is taking advantage of the opportunities now afforded
by the 2018 Farm Bill. In a recent press release (http://ibn.fm/oqaDm), the
company announced a change in staff. David Barbash has been signed on as its
new chief sales officer, beginning in 2019. He brings more than 20 years of new
business development experience and is a proven negotiator, manager and
motivator. Barbash will be responsible for distributing CBD products through
his nationwide retail accounts. Jill Buzan, ETST’s current chief sales officer,
is transitioning to direct ETST’s sales in Florida.
In a news release, Nickolas S. Tabraue, president, director
and chairman of ETST, stated, “[Barbash’s] expertise and enthusiasm will be
tremendous assets as we ride the wave opportunity afforded by the legalization
of hemp cultivation and hemp-derived CBD in the United States.”
The company also recently announced its first commercial
production run of Hygee Kits (http://ibn.fm/pDNhr).
The self-sampling kits enable women to discreetly test for sexually transmitted
infections (STIs) such as chlamydia. The World Health Organization (WHO)
recommends that women between the ages of 15 and 25 who are sexually active get
tested yearly for chlamydia. This demographic represents a market of
approximately 500 million women worldwide. Initial marketing for this first
product run will target North America, South America, Asia and Africa.
Packaging for the kits will be available in English, French, Portuguese,
Spanish, Vietnamese and Arabic.
Hygee is convenient, efficient, affordable and anonymous. It
is considered a ‘mistake-proof’ medical device that comes with simple
instructions that allow for successful use on the first try. According to
WHO, there are approximately 130 million new chlamydia cases diagnosed each
year. Pregnant women are screened to minimize the risk of transmitting the
infection to their babies during childbirth. Chlamydia is a global issue, and
sales of Hygee are projected to reach between $1.5 million and $2.5 million in
the first year. Second year sales are projected to reach $1 million monthly,
and, by the third year, sales are expected to rise to $20 million yearly. By
2023, the global medical device market is anticipated to surpass $400 billion (http://ibn.fm/u3YfU). While Hygee
is set to be launched early in 2019 for the detection of chlamydia, it is only
the beginning in terms of what the company has planned in the medical device
space.
“We believe that ETST has developed the best tool on the
market to fight STIs, which will provide an exceptional service to women who
use Hygee,” added Tabraue. “The production of the first batch of Hygee is
very exciting. Our team believed in the success of Hygee from the first
day we acquired it. Now, we will do everything possible to spread this fabulous
medical device everywhere on the planet to protect women and their future
babies from the terrible, adverse effects of chlamydia and other STIs.”
For more information, visit the company’s website at www.EarthScienceTech.com
About QualityStocks
QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential. We offer several ways for investors to learn more
about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php

No comments:
Post a Comment